Voriconazole-UK-109496-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEVoriconazoleCat. No.: HY-76200CAS No.: 137234-62-9Synonyms: UK-109496分式: CHFNO分量: 349.31作靶点: Fungal作通路: Anti-infection储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 50 mg/mL (143.14 mM)H2O

2、 : 0.17 mg/mL (0.49 mM; Need ultrasonic)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.8628 mL 14.3139 mL 28.6279 mL5 mM 0.5726 mL 2.8628 mL 5.7256 mL10 mM 0.2863 mL 1.4314 mL 2.8628 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验请根据您的实验动物和给药式选择适当的溶解案

3、，配制前请先配制澄的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄的储备液可以根据储存条件，适当保存；以下溶剂前的百分指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (7.16 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)1/2 Master of Small Molecules 您边的抑制剂师www.MedChemE

4、Solubility: 2.5 mg/mL (7.16 mM); Clear solution3. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (7.16 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Voriconazole(UK-109496)第代三唑类抗真化合物，可作于严重 的真感染。 Med Mycol. 2018 Jun 1;56(4):452-457.See more customer validations on HYPERLINK / www.MedChemEREFERENCE

5、S1. Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics. 2011Jun;12(6):861-72. doi: 10.2217/pgs.11.18.2. Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole

6、 inrelation to CYP2C19 genotype. Br J Clin Pharmacol. 2009 Dec;68(6):906-15. doi: 10.1111/j.1365-2125.2009.03534.x.3. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther. 2004 Aug;2(4):485-97.4. Louis D. Saravolatz, Section Editor, Leonard B. Johnson,

7、 et al. Voriconazole: A New Triazole Antifungal Agent. Clin Infect Dis. 2003,36(5): 630-637.5. John R. Perfect, Kieren A. Marr, Thomas J. Walsh, et al. Voriconazole Treatment for Less-Common, Emerging, or Refractory FungalInfections. Clin Infect Dis. 2003, 36 (9): 1122-1131.McePdfHeightCaution: Product has not been fully validated for medical applications.For research us